- Home
- YXT vs ADVM Comparison
YXT vs ADVM Comparison
Compare YXT & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- ADVM
- Stock Information
- Founded
- YXT 2011
- ADVM 2006
- Country
- YXT China
- ADVM United States
- Employees
- YXT N/A
- ADVM N/A
- Industry
- YXT
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YXT
- ADVM Health Care
- Exchange
- YXT NYSE
- ADVM Nasdaq
- Market Cap
- YXT 129.2M
- ADVM 119.6M
- IPO Year
- YXT 2024
- ADVM 2014
- Fundamental
- Price
- YXT $2.31
- ADVM $4.74
- Analyst Decision
- YXT
- ADVM Strong Buy
- Analyst Count
- YXT 0
- ADVM 6
- Target Price
- YXT N/A
- ADVM $27.83
- AVG Volume (30 Days)
- YXT 85.1K
- ADVM 247.3K
- Earning Date
- YXT 11-26-2024
- ADVM 11-04-2024
- Dividend Yield
- YXT N/A
- ADVM N/A
- EPS Growth
- YXT N/A
- ADVM N/A
- EPS
- YXT 3.06
- ADVM N/A
- Revenue
- YXT $48,030,651.00
- ADVM $1,000,000.00
- Revenue This Year
- YXT N/A
- ADVM N/A
- Revenue Next Year
- YXT N/A
- ADVM N/A
- P/E Ratio
- YXT $0.75
- ADVM N/A
- Revenue Growth
- YXT N/A
- ADVM N/A
- 52 Week Low
- YXT $1.90
- ADVM $4.61
- 52 Week High
- YXT $11.00
- ADVM $29.70
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- ADVM 26.02
- Support Level
- YXT N/A
- ADVM $5.65
- Resistance Level
- YXT N/A
- ADVM $5.33
- Average True Range (ATR)
- YXT 0.00
- ADVM 0.37
- MACD
- YXT 0.00
- ADVM -0.09
- Stochastic Oscillator
- YXT 0.00
- ADVM 5.65
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.